- Home
- RAND vs AADI Comparison
RAND vs AADI Comparison
Compare RAND & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- AADI
- Stock Information
- Founded
- RAND 1969
- AADI 2011
- Country
- RAND United States
- AADI United States
- Employees
- RAND N/A
- AADI N/A
- Industry
- RAND Finance: Consumer Services
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- AADI Health Care
- Exchange
- RAND Nasdaq
- AADI Nasdaq
- Market Cap
- RAND 47.5M
- AADI 51.7M
- IPO Year
- RAND N/A
- AADI N/A
- Fundamental
- Price
- RAND $16.77
- AADI $2.04
- Analyst Decision
- RAND
- AADI Hold
- Analyst Count
- RAND 0
- AADI 3
- Target Price
- RAND N/A
- AADI $1.75
- AVG Volume (30 Days)
- RAND 1.3K
- AADI 94.4K
- Earning Date
- RAND 11-04-2024
- AADI 11-06-2024
- Dividend Yield
- RAND 6.92%
- AADI N/A
- EPS Growth
- RAND 72.67
- AADI N/A
- EPS
- RAND 4.19
- AADI N/A
- Revenue
- RAND $7,874,601.00
- AADI $23,817,000.00
- Revenue This Year
- RAND N/A
- AADI $4.79
- Revenue Next Year
- RAND N/A
- AADI $10.72
- P/E Ratio
- RAND $4.00
- AADI N/A
- Revenue Growth
- RAND 13.24
- AADI 10.57
- 52 Week Low
- RAND $12.50
- AADI $1.21
- 52 Week High
- RAND $19.60
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- RAND 48.90
- AADI 61.09
- Support Level
- RAND $16.39
- AADI $2.05
- Resistance Level
- RAND $17.26
- AADI $2.17
- Average True Range (ATR)
- RAND 0.28
- AADI 0.09
- MACD
- RAND 0.00
- AADI -0.00
- Stochastic Oscillator
- RAND 43.68
- AADI 63.93
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.